Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PTSD memory eraser trial for teens pulled before it began

NCT ID NCT04921982

Disease control Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study aimed to see if the blood pressure drug propranolol could reduce PTSD symptoms in adolescents by blocking the reconsolidation of traumatic memories. Participants would have taken propranolol or a placebo before briefly recalling their trauma, once a week for six weeks. However, the trial was withdrawn before enrolling any teens, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Propranolol
What this could lead to
If it had worked, this could have pointed toward a new way to treat PTSD in teens by weakening traumatic memories.
What could go wrong
The trial was withdrawn before any participants were enrolled, so no results are available. Even if it had run, it was a small early-phase study, and propranolol's effect on memory is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

Oct 2024

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Adolescents aged 12 to 18 years; * Exposed to a single traumatic event or to events circumscribed in time, including sexual abuse in the absence of reminders in the environment; * Fluent in French; * Positive diagnosis of PTSD with the SCID-5; * Disorders evolving for at least three months; * Heart rate ≥ 55 bpm; * Systolic blood pressure ≥ 100 mmHg; * Written parental or legal guardian consent; * Written agreement by the adolescent; * Adolescents affiliated, via their parents, to the French social security body. Exclusion Criteria: * \- Medical condition contraindicating administration of propranolol (COPD, asthma, cardio-vascular insufficiency, heart failure as second- and third-degree atrioventricular blocks, Prinzmetal angor, pheochromocytoma, Raynaud disease, history of an anaphylactic reaction, sinus node disease, hypoglycemia, AV blocks) * Known chronic renal or hepatic insufficiency * Schizophrenia; * Mental retardation; * Autism spectrum disorder; * Acute severe suicidal ideation * Traumatic brain injury (loss of consciousness \> 10 minutes); * Currently treated for substance or alcohol dependence; * Currently treated for Attention Deficit Hyperactivity Disorder; * Currently treated with a drug that can interfere with propranolol and that can represent a danger according to medical advice if it's suspended more than 24 hours. * Currently treated with a bradycardic drug; * Concurrent psychotropic medication with the exception of cyamemazine (suspended 48 hours before session) * Concurrent trauma-focused psychotherapy in progress or stopped less than 1 month ago; * Pregnancy or breast feeding. * Current use of "recreative" toxic drugs * Concurrent participation to another interventional study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-traumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-traumatic stress disorder

Contacts and locations

Locations

  • AP-HP Louis Mourier

    Colombes, France

  • CH Bohars

    Bohars, France

  • CH Guillaume Régnier

    Rennes, 35000, France

  • CH Le Havre

    Le Havre, France

  • CHU Angers

    Angers, France

  • CHU Besançon

    Besançon, France

  • CHU Limoges

    Limoges, France

  • CHU Nantes

    Nantes, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rouen

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.